Revolution Medicines Inc Stock News

REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib), th...

2026 is the year of the cancer breakthrough, with innovations from Revolution Medicines and Moderna. "I'm almost tired of saying paradigm shift, but I haven't figured out a new phrase," one expert said.

REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that The New England Journal of Medicine (NEJM) has published a report describing data from the Phase 1/2 clinical trial eva...

Revolution Medicines attracted takeover interest but decided to go it alone. This week's FDA approval of its pancreatic cancer pill is the payoff.

This release contains multimedia assets available for download here

Revolution Medicines won FDA approval Wednesday for the pancreatic cancer treatment that once caused its stock to skyrocket.

Daraxonrasib, the pill touted by a former member of Congress and cancer patient as a ‘miracle drug,' has been granted approval in patients with pancreatic adenocarcinoma.

The FDA approved a therapy from Revolution Medicines that slows a cancer that kills 7 of out 8 patients within five years.